Treatment for Lifting Upper Arm Lax Skin

Safety and Efficacy of Sofwave Treatment to Lift Upper Arm Lax Skin

Open-label, non-randomized, prospective, multi-center, self-controlled clinical study with masked evaluation.

Study Overview

• Status: Completed
• Conditions: Lax Skin
• Intervention / Treatment: Device: Sofwave

Detailed Description

Eligible patients will receive 2 treatments on both upper arms (4-6 weeks apart) using the Sofwave System.

Treatment may be administered after the enrollment and screening at the first visit, or it may occur later following the enrollment and screening activities based on site scheduling availabilities. All patients will return to the clinic for follow up visit at 3 months ± 2 weeks post last treatment (FU1).

Methodology described in the protocol to evaluate efficacy and safety of treatments will be carried out at each visit at the clinic.

• Study Type: Interventional
• Enrollment (Actual): 50
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • California
    • Sacramento, California, United States, 95816
      • Laser & Skin Surgery Center of Northern California
  • Illinois
    • Lincolnshire, Illinois, United States, 60069
      • Advanced Dermatology
  • New York
    • New York, New York, United States, 10016
      • Laser & Skin Surgery Center of New York®
  • Pennsylvania
    • Ardmore, Pennsylvania, United States, 19003
      • Main Line Center for Laser Surgery

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 35 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Male or female subjects > 35 years of age and < 70 years of age.
2. Not pregnant or lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide) or abstinence.
3. Desire to undergo upper arms skin lax lifting treatments.
4. Subject has clearly visible lax skin on the upper arm, which in the investigator's opinion, may benefit from the treatment.
5. Subject agrees to maintain his/her weight (i.e., within 5% of total body weight) by not making any major changes in their diet or exercise routine during the course of the study.
6. Able and willing to comply with all visits, treatments and evaluations schedules and requirements.
7. Willing to have research photos taken of treatment areas.
8. Subject agrees not to undergo any other upper arm skin lax treatments for a period of 3 months following Sofwave treatment.
9. Able to understand and provide written Informed Consent.

Exclusion Criteria:

1. Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding.
2. Skin disorders (skin infections or rashes, extensive scarring, psoriasis, etc.) in the treatment area.
3. Medical disorder that would hinder the wound healing or immune response (such as blood disorder, inflammatory disease, etc.).
4. History of Epileptic seizures.
5. Known allergy to lidocaine or epinephrine or antibiotics.
6. Active malignancy or history of malignancy in the past 5 years.
7. Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders (i.e. any disease state that in the opinion of the investigator may interfere with the anesthesia, treatment, or healing process).
8. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
9. Suffering from hormonal imbalance, whether related to thyroid, pituitary, or androgen.
10. History of significant lymphatic drainage problems.
11. Currently heavy smoker or has history of heavy smoking (25 cigarettes per day or more) in past 10 years.
12. History of chronic drug or alcohol abuse.
13. History of bleeding disorder or is taking any medication that in the investigator's opinion may increase the subject's risk of bruising.
14. Currently taking or has taken diet pills or weight control supplements within the past month.
15. BMI>=30kg/m2
16. Non-stable weight nominally ±5% for at the past month.
17. Active implanted device such as a pacemaker, defibrillator, or drug delivery system.
18. History of epidermal or dermal disorders (particularly involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders.
19. History of a fat reduction procedure (e.g., liposuction, surgery, lipolytic agents, etc.).
20. History of prior surgery in the upper arms.
21. Excessive subcutaneous fat on the upper arms.
22. Severe solar elastosis on the intended to treat area.
23. Significant scarring, atrophic scars in the area to be treated, or has a history of atrophic scars or keloids or prone to bruising.
24. Tattoo or former tattoo at or near treatment area.
25. Presence of an implant in or adjacent to area of intended treatment (upper arms).
26. History of ablative or non-ablative resurfacing/rejuvenation laser treatment or light treatment within the past 6 months, dermabrasion or deep peeling within the past 12 months on the intended to treat area.
27. Inability to understand the protocol or to give informed consent.
28. On-going use of psychiatric medication.
29. Unable or unwilling to comply with the study requirements and procedures.
30. Currently enrolled in a clinical study of any other unapproved investigational drug or device.
31. Any other condition that would, in the professional opinion of the investigator, potentially affect the subject's response or the integrity of the data or would pose an unacceptable risk to the subject.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Upper Arm	Device: Sofwave; The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.; Other Names: SUPERB

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of improvement of upper arms lax skin	following Sofwave treatment as evaluated by independent masked reviewers	1 year

Collaborators and Investigators

• Sponsor: Sofwave Medical LTD
• Investigators: Study Director: Ruthie Amir, MD, CMO

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2022
• Primary Completion (Actual): February 1, 2023
• Study Completion (Actual): February 1, 2023

Study Registration Dates

• First Submitted: April 19, 2022
• First Submitted That Met QC Criteria: April 27, 2022
• First Posted (Actual): May 3, 2022

Study Record Updates

• Last Update Posted (Estimated): November 17, 2023
• Last Update Submitted That Met QC Criteria: November 16, 2023
• Last Verified: March 1, 2022

More Information

Terms related to this study

• Keywords: upper arms, lax skin
• Additional Relevant MeSH Terms: Skin Diseases; Genetic Diseases, Inborn; Connective Tissue Diseases; Skin Diseases, Genetic; Cutis Laxa
• Other Study ID Numbers: Sofwave07

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No